QRxPharma is a specialty pharmaceutical company with a pipeline of patented drugs for the treatment of chronic and acute pain. It is to shortly to commence Phase III trials in the USA and Australia. QRx Pharma Limited (ASX:QRX), listed on ASX on Friday 25th May, 2007.

The company is targeting the US$7bn opiod pain market in the USA. As 1500 pain specialists are responsible for 30% of the prescriptions in this market, the Company plans to utilise its own specialty sales force when it commences sales in about three years.

Innovation Capital led the venture investment in the company when it was founded in 2002 based on technology developed at the University of Queensland. The company has offices in Sydney, Australia and Maryland USA.